Smith+Nephew

Prepare + Protect + Progress

A burn care solution for every step of the way

VERSAJET◊ II
Hydrosurgery System

Collagenase
SANTYL◊
Ointment 250 units/gram

ACTICOAT◊
Antimicrobial Barrier Dressings



OASIS®
Matrix Products



BIOBRANE◊
Temporary Biosynthetic
Wound Dressing



The impact of burns

Burn injuries affect patients of all ages, but age plays a critical role in both recovery time and survival rates.

Pediatric patients

18%

0-21 years make up 18% of total cases of U.S. burn population[1]

<1%

While their **mortality rate remains low** (<1%)[1], burns are still among the **top ten leading causes** of unintentional death for children[2]

1.0-1.4

Their ability to **recover faster** is reflected in their shorter length of stay (LOS) in hospitals—**just 1.0 to 1.4 days per percent total body surface area (TBSA) burned**[1]

Older adults

17%

>65 years account for 17% of total burn cases in the U.S., a number expected to grow as the aging population increases[1,2]

9.8%

Risks for this group are significantly higher with mortality rates jumping up to **9.8% at age 65 and rising to 14.3% at 80+ years**[1,3]

3.3-3.4

Recovery is also more challenging, with **hospital stays nearly tripling** compared to younger patients—**3.3 - 3.4 days per percent TBSA burned**[1]

Prepare ✚ Protect ✚ Progress

Prepare for proper wound bed preparation



Delayed Excision correlated to higher patient age[1]

Pediatric Population = within 1 day

Older Adult Population = >4 days

With the right tools, preparing the wound early creates the best conditions for recovery. By removing damaged tissue sooner, our burn solutions help reduce the risk of infection and sepsis.[4]

Reference: 1. Jackson DM. The diagnosis of the depth of burning. Br J Surg 1953; 40:588-96. **2.** Shupp JW, et al. A review of the local pathophysiologic bases of burn would progession. J Burn Care Res., 2010

Protect against infections and complications



Sepsis leads to

50%

of the pediatric mortality rate[6]

Complications with septicemia being the most common

~33%

contribute significantly to mortality in the older adult population.[6]

In burn care, infection control is everything. Our burn solutions provide an added layer of defense against the spread of bacteria.[4] It's possible to protect the wound and support recovery.

Progress towards burn wound closure



Cellular proliferation

Synthetic and Biosynthetic Membranes:

2,584 cases across[1]

40 burn centers[1]

Wound Matrix:

547 cases across[1]

34 burn centers[1]

Wound matrices should do more than just cover a wound. Our burn solutions keep recovery on track by supporting re-epithelization.[7-11] They provide coverage, flexibility, and support needed to help patients progress toward closure.

Prepare ✚ Protect ✚ Progress

How burn care moves patients forward

Burn injuries require a strategic, multi-step approach to minimize complications, prevent infection, and accelerate recovery. From the first treatment to final closure, our portfolio helps support your burn patients at every stage of their recovery.

Smith+Nephew provides an extensive and clinically proven portfolio of burn care solutions for treating a wide range of burns and burn-related conditions, catering to both pediatric and adult patients, from inception of injury through completion of treatment and beyond.

Prepare - VERSAJET◊ System ✚ SANTYL◊ Ointment

VERSAJET◊ II
Hydrosurgery System

Collagenase SANTYL◊
Ointment 250 units/gram

Protect - ACTICOAT◊ Dressings

ACTICOAT◊
Antimicrobial Barrier Dressings

Progress – BIOBRANE◊ Dressing ✚ OASIS® Wound Matrix



BIOBRANE◊
Temporary Biosynthetic Wound Dressing

OASIS®
Wound Matrix

Prepare - VERSAJET◊ II Hydrosurgery System

Accelerate your surgical debridement[19-21]

Surgeons trust the scalpel as a tried-and-true tool for debridement. But delayed excision correlates with higher patient age.[1] Pediatric patients require excision within 1 day, while older adults could face delays of 4 days or more—increasing complications and prolonging recovery.[1]

What if there was a faster way?

Debridement: simplified and precise

The VERSAJET II Hydrosurgery System accelerates surgical debridement for burns, chronic, and acute wounds, combining the power of a scalpel and suction into one seamless tool. With greater precision and efficiency, the VERSAJET II Hydrosurgery System provides a smoother, more regular wound bed, which can lead to improved skin graft procedures.[20, 22, 23*]

A surgeon's edge in burn care

The VERSAJET II Hydrosurgery System gives you the precision you need to streamline debridement and support wound progression:



Selects necrotic tissue and debris with a localized vacuum for precise removal[23-26]



Excises non-viable tissue with maximum precision, minimizing unnecessary tissue loss[23-26]



Evacuates debris and slough while preserving healthy tissue to support wound progression[23-26]

*Compared to conventional debridement

Prepare - VERSAJET◊ II Hydrosurgery System

Every step matters, every second counts

The VERSAJET II Hydrosurgery System provides controlled debridement and facilitates the removal of necrosis and other unwanted material from the wound surface, preserving viable tissue.[14, 16, 20-28]

With the VERSAJET System, you're **preparing, protecting,** and **progressing** every burn wound toward closure. In burn care, time is critical**—make every move count.**

Conventional surgical excision



VERSAJET◊ II Excision



Adapted from Cubison TC, Pape SA, Jeffery SL. *Burns*. 2006;32:714-720.

Precisely control the depth of debridement[24]

Tangential excision (Goulian knife, 10 guard)

Excises at an average depth of 750µm[24]

VS



VERSAJET System

Enables precise excision at a minimum depth of 50µm[24]

Learn how VERSAJET Hydrosurgery II can transform your approach to burn care.

Prepare - Collagenase SANTYL◊ Ointment

Every burn needs a plan. Start with SANTYL Ointment

Preparation is everything when it comes to burn care. Currently, 47% of all burn cases require skin excision or replacement surgery, and with the median TBSA increasing, so does the need for surgical intervention.[1] The right debridement approach can make all the difference in wound bed optimization, setting the foundation for improved outcomes.

Collagenase SANTYL Ointment breaks down necrotic tissue preparing the wound for the next phase of care while supporting wound progression.[29-32]

Burns need direction. Are you setting them up for success?

A burn's severity can change over time—what starts as a partial-thickness injury can worsen, leading to deeper damage and more tissue loss. **The good news?** Early debridement with SANTYL Ointment can help. By clearing away necrotic tissue, SANTYL Ointment supports the wound environment and may help slow burn conversion,[29-32]giving the wound a better chance to recover.

You could wait for a burn to declare itself...or you could take a proactive approach



Zone of stasis salvaged

Zone of stasis converts to necrosis

Important Safety Information: Indications: Collagenase SANTYL◊ Ointment ("SANTYL") is indicated for debriding chronic dermal ulcers and severely burned areas. **Contraindications:** SANTYL is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase. **Warnings and Precautions:** The optimal pH range of collagenase is 6 to 8. Higher or lower pH conditions will decrease the enzyme's activity and appropriate precautions should be taken. The enzymatic activity is also adversely affected by certain detergents, and heavy metal ions such as mercury and silver which are used in some antiseptics. As such, the wound should be properly cleansed prior to application of SANTYL. Debilitated patients should be closely monitored for systemic bacterial infections because of the theoretical possibility that debriding enzymes may increase the risk of bacteremia. A slight transient erythema has been noted occasionally in the surrounding tissue, particularly when SANTYL was not confined to the wound. SANTYL is not indicated for wound closure. Discontinue use of SANTYL after granulation tissue is well-established. **Adverse Reactions:** No allergic sensitivity or toxic reactions have been noted in clinical use when used as directed. The risk information provided herein is not comprehensive. To see the complete Prescribing Information, please see the FDA-approved product labeling, here: https://www.santyl.com/pdf/SANTYL-PI.pdf. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

Prepare - Collagenase SANTYL◊ Ointment

For partial-thickness burns in the zone of stasis, what's your strategy?

Burn stabilization

Surgical debridement

Depth evaluation

Tissue preservation

Partial-thickness burn

Partial-thickness burn

Clostridium Collagenase Impact on Zone of Stasis Stabilization and Transition to Healthy Tissue in Burns[33]

Rosanne E Frederick , Robert Bearden , Aleksa Jovanovic , Nasreen Jacobson , Rajiv Sood , Sandeep Dhall

- **Animal study design:** Classic burn comb model (porcine)
- **Products:** Clostridium Collagenase suspended in hydrogel vs. hydrogel control
- **Objective:** Evaluation of clostridium collagenase's ability to effectively minimize burn progression
- **Methods:** Clostridium collagenase or control vehicle daily and biopsied at various time points. Biopsies were evaluated for factors associated with progressing necrosis as well as inflammatory response associated with treatment

Study results:

Debridement with collagenase stabilized the zone of stasis and limited burn conversion by:

- Digesting devitalized collagen
- Resolving Inflammation
- Maintaining vascular networks

Protect - ACTICOAT◊ Antimicrobial Barrier Dressings



A strong defense for every burn wound

Burn injuries leave patients vulnerable. Infection is one of the biggest risks, and the consequences can be severe. Septicemia accounts for nearly 33% of burn-related deaths in older adults, while sepsis contributes to 50% of pediatric burn mortality cases.[34, 35] ACTICOAT Dressing is effective against over 150 pathogens.*[37-41]

ACTICOAT Dressing Antimicrobial Barrier Dressing:

Starts killing bacteria as little as **30 minutes** *in vitro*[36, 41-46]

Effective against a broad spectrum of bacteria and fungi*[36-38, 40-42, 47]

Flexible and conforming to reduce trauma during dressing changes†[48, 49]

*As demonstrated *in vitro*
†ACTICOAT Dressing Flex 3 and Flex 7

Early ACTICOAT Dressing application **helps minimize** progression to systemic infection, and the number of surgical procedures while achieving an overall cost of treatment reduction.[50-56]

Early intervention is key. By applying ACTICOAT Dressing at the first signs of risk, you're taking an active step in helping protect burn patients from infections and giving them the best chance at recovery.

ACTICOAT Dressings prevent and manage symptoms of infections in burn wounds[54,86]

80%

Fewer infections

When applied early in addition to standard treatment, ACTICOAT Dressing led to a significant decrease of burns becoming infected, from **55% to 10.5%, a decrease of 80%**, compared to standard treatment plus silver sulfadiazine cream.*[54]

*Standard treatment included daily showers and/or 4% chlorhexidine soap

90%

Fewer antibiotic treatments

With ACTICOAT Dressing, fewer patients developed cellulitis, dramatically reducing the need for antibiotics from **57% to 5.2%** of cases compared to daily chlorhexidine soap and silver sulfadiazine cream.[86]

Protect - ACTICOAT◊ Antimicrobial Barrier Dressings

Explore how the full ACTICOAT Dressing portfolio can shield your work

ACTICOAT Dressing

Trusted protection for short-term wound management

- A three-layer dressing that provides up to 3 days of continuous antimicrobial protection[37, 38, 40, 47]
- Designed with Nanocrystalline Silver-coated mesh, ACTICOAT Dressing helps prevent and minimize the risk of infection.[50, 57-60]
- A smart choice for burns and wounds that require frequent dressing changes, helping with effective infection control without compromising wound care[47, 50]

ACTICOAT 7 Dressing

Long-lasting protection for complex wounds

- A five-layer dressing designed for up to 7 days of antimicrobial protection[61, 62]
- Features three layers of Nanocrystalline Silver-coated mesh which has been shown to manage bioburden.[53, 54, 63]
- Delivers sustained antimicrobial activity, making it ideal for burns and wounds requiring frequent dressing changes[50, 61, 62]

ACTICOAT FLEX 3 and Flex 7 Dressing

Highly conformable for chronic wounds

- A flexible, low-adherent dressing made of woven fabric and coated with Nanocrystalline Silver for antimicrobial defense[58, 64-67]
- Provides a strong antimicrobial barrier for up to 3 days (Flex 3) or up to 7 days (Flex 7), fighting a broad spectrum of bacteria[37, 38, 40]
- Compatible with negative pressure wound therapy, delivering sustained protection for up to 3 days[68-71]

Progress - BIOBRANE◊ Temporary Biosynthetic Wound Dressing



Give wounds the best chance to heal

With **2,584 cases across 40 burn centers**[1], biosynthetic membranes like BIOBRANE Temporary Biosynthetic Wound Dressing are a necessity in burn care. Designed to support wound progression, BIOBRANE Dressing offers a **flexible solution with real-time monitoring**[72] that helps facilitate epithelialization,[39-47] while allowing direct wound inspection. Burn care isn't just about helping your patients reach recovery; it's about how your patients recover.

Discover how BIOBRANE Dressing can support your patients' progress:

Reduced healing time: Helps accelerate healing and supports epithelialization. May lead to quicker discharge and fewer hospital days.*[7-10, 73-77]

Less pain, more comfort: Designed for patient comfort with significant pain relief reported.†[7, 8]

See the progress: Transparency allows for real-time wound inspection without unnecessary dressing changes.[73, 74, 76]

Versatile for various wounds: Indicated for partial-thickness burns and split-thickness donor sites. Can be used in adult and pediatric populations.[77-79]

Minimize pain and facilitate healing over partial-thickness burns and donor sites on adults and pediatric patients after BIOBRANE Dressing in applied.†*[64,65]



Try a solution that works just as hard as you do
BIOBRANE Dressing helps patients move forward faster

*Compared to Silver Sulfadiazine (SSD)
†p<0.001

Progress - OASIS® Wound Matrix

Move wounds forward with OASIS

Burn injuries come with complex challenges, from infection risks to scarring and prolonged healing times. With 547 cases across 34 burn centers, wound matrices, like OASIS Wound Matrix, have proven to be a reliable solution for burn wound management.[1]

OASIS Wound Matrix is a versatile, bioresorbable scaffold designed to support the body's natural ability to repair and replace damaged tissue. OASIS provides a flexible solution that supports **faster epithelialization**,[80] **less scarring**,[80-82] and **improved patient comfort**.[80]

Simple to store. Easy to use. Clinically proven.

100% closure of second-degree burns in 7-14 days [82]



More mature epidermis and earlier granulation compared to Suprathel[80]

No complications, no infections, and good aesthetic outcomes[80-82]

A smarter approach to burn wound management

OASIS Wound Matrix offers a cost-effective solution for wound care, supporting healthy tissue regeneration while helping to minimize scarring and improving patient outcomes.[50-54, 80-85]

- **Speeds up** epithelialization for faster burn closure[80]
- **Helps reduce** the need for painful dressing changes[80]
- **Preserves** viable tissue, supporting long-term recovery[82, 83, 84]
- **Minimizes** patient discomfort, improving quality of care[80]

Indicated for deep partial-thickness burn wounds. OASIS is similar in composition to the human dermis, promoting cellular migration and vascular growth. It's versatile, cost-effective,[85] and improves wound healing compared to standard care.

OASIS Wound Matrix is derived from a porcine source and should not be used in patients with known sensitivity to porcine materials. This device is not indicated for use in third degree burns.

Product list

Our portfolio continues to meet your burn needs

Additional Smith+Nephew products listed below

- CICA-CARE◊ Silicone Gel Sheet
- CONFORMANT◊ 2 Non-Adherent Contact Layer
- CUTICERIN◊ Low Adherent Tulle Gras Dressing
- EXU-DRY◊ Specialty Absorptive Wound Dressing
- GRAFIX◊ Cryopreserved Placental Membrane
- GRAFIX PL◊ PRIME Lyopreserved Placental Membrane
- INTRASITE◊ GEL Hydrogel Wound Dressing
- PICO◊ Single Use Negative Pressure Wound Therapy (NPWT) System
- RENASYS◊ TOUCH Negative Pressure Wound Therapy System
- SOLOSITE◊ Wound Gel
- STRAVIX◊ Cryopreserved Umbilical Tissue

Ordering information

ACTICOAT◊ Dressing

Order No	Size	Each/unit	Unit/case	HCPCS
20101	4" x 4"	12	4	A9270
20201	4" x 8"	12	4	A9270
20301	8" x 16"	6	4	A9270
20401	16" x 16"	6	2	A9270
20501	4" x 48"	6	2	A9270
20601	2" x 2"	5	20	A9270
20151	5" x 5"	5	5	A9270

ACTICOAT◊ 7 Dressing

Order No	Size	Each/unit	Unit/case	HCPCS
20341	2" x 2"	5	20	A9270
20141	4" x 5"	5	6	A9270
20241	6" x 6"	5	4	A9270

ACTICOAT◊ Flex 3 Dressing

Order No	Size	Each/unit	Unit/case	HCPCS
66800402	2" x 2"	5	20	A6206
66800406	4" x 4"	12	4	A6207
66800417	4" x 8"	12	4	A6207
66800418	8" x 16"	6	4	A6208
66800433	16" x 16"	6	2	A6208
66800434	4" x 48"	6	2	A6208

ACTICOAT◊ Flex 7 Dressing

Order No	Size	Each/unit	Unit/case	HCPCS
66800403	2" x 2"	5	20	A6206
66800405	4" x 5"	5	6	A6207
66800427	6" x 6"	5	4	A6207
66800407	8" x 16"	6	4	A6208
66800408	16" x 16"	6	2	A6208
66800544	1" x 24"	5	10	A6207

BIOBRANE◊ Temporary Wound Dressing

Order No	Size	Unit/carton
66027700	5.1in x 5.1in / 13cm x 13cm	5
66027701	5.1in x 15 in / 13cm x 38cm	5
66027702	9.8in x 15in / 25cm x 38cm	1
66027703	15in x 19.7in / 38cm x 50cm	1

BIOBRANE◊ Temporary Wound Glove

Order No	Size	Unit/carton
66027704	Small Glove	2
66027705	Medium Glove	1
66027706	Large Glove	1
66027707	Pediatric Glove	1

CICA-CARE◊ Adhesive Silicone Gel Sheet

Order No	Size	Each/unit	Unit/case	HCPCS
66250707	5" x 6"	10	1	A6025

CONFORMANT◊ 2 Wound Veil

Order No	Size	Each/unit	Unit/case	HCPCS
5955044	4" x 4"	1	48	A6206
5955412	4" x 12"	1	48	A6207
59551212	12" x 12"	1	48	A6208
59551224	12" x 24"	1	48	A6208
59552436	24” x 36”	1	50	A6208
5955305	3” x 5yd	1	20	A6206 - A6208
5955602	6” x 2yd	1	20	A6206 - A6208

CUTICERIN◊ Low-Adherent Surgical Dressing

Order No	Size	Each/unit	Unit/case	HCPCS
66045562	3" x 3"	10	12	A6222
66045560	3" x 3"	50	6	A6222
66045564	4" x 4"	10	12	A6222
66045503	3" x 8" (3/pkg)	25	6	A6223
66045563	3" x 8"	10	12	A6223
66045561	3" x 8"	50	6	A6223
66045502	8" x 16"	25	6	A6224

Ordering information

EXU-DRY◊ Anti-Shear Wound Dressing

Order No	Size	Each/unit	Unit/case	HCPCS
5999M36	24" x 36" Pads/Sheets	1	15	A6253
5999M37	24" x 36" Pads/Sheets	1	24	A6253
5999L72	36" x 72" Pads/Sheets	1	15	A6253
5999L73	36" x 72" Pads/Sheets	1	15	A6253
5999L74	36" x 72" Pads/Sheets	1	15	A6253
5999LPA	Arm	1	20	A6253
5999LPG	Large Hand	1	20	A6253
5999MPG	Medium Hand	1	20	A6253
5999FM1	Adult Face	1	20	A6253
5999LPL	Leg	1	20	A6253
5999003S	3” Slit Disc (M) Wound Dressing	1	100	A6251
5999003	3” Disc Wound Dressing	1	100	A6251
5999034	3” x 4” Wound Dressing	1	100	A6251
5999004120	4” x 6” (F) Wound Dressing	1	120	A6252
5999006	6” x 9” (F) Wound Dressing	1	48	A6253
5999009	9” x 15” (F) Wound Dressing	1	30	A6253
5999018	15” x 18” (F) Wound Dressing	1	30	A6253
5999024	15” x 24” (F) Wound Dressing	1	30	A6253
5999028	20" x 28" (F) Wound Dressing	1	20	A6253
5999PTM	2” x 3” Slit Tube (F) Wound Dressing	1	50	A6251
5999034S	3” x 4” Slit Tube (F) Wound Dressing	1	50	A6252
5999101	4” x 6” Slit Tube (F) Wound Dressing	1	100	A6253
5999034	3” x 4” Wound Dressing	1	100	A6251
5999LJ1	Large Burn Torso Jacket	1	10	A6253
5999MJ1	Medium Burn Torso Jacket	1	10	A6253
5999LV1	Large Burn Vest	1	20	A6253
5999BP1	Adult Buttocks Vest	1	10	A6253

INTRASITE◊ Gel Hydrogel Wound Dressing

Order No	Size	Each/unit	Unit/case	HCPCS
66027308	.28oz	10	4	A6248
66027311	.52oz	10	4	A6248
66027313	.88oz	10	4	A6248

Collagenase SANTYL◊ Ointment 250 units/g

Order No	Size	Each/unit	Unit/case	HCPCS
50484-010-30	30gm tube	1	12	NDC: 50484-010-30
50484-010-90	90gm tube	1	12	NDC: 50484-010-90

GRAFIX◊ Cryopreserved Placental Membrane

Order No	Size	Each/ unit	Unit/ case	HCPCS
PS60013	GRAFIX PRIME 16mm disc (2cm^2)	1	1	Q4133
PS11015	GRAFIX PRIME 1.5cm x 2cm (3cm^2)	1	1	Q4133
PS11023	GRAFIX PRIME 2cm x 3cm (6cm^2)	1	1	Q4133
PS11034	GRAFIX PRIME 3cm x 4cm (12cm^2)	1	1	Q4133
PS11055	GRAFIX PRIME 5cm x 5cm (25cm^2)	1	1	Q4133
PS24075	GRAFIX XC 7.5cm x 15cm (113cm^2)	1	1	Q4133
PS12023	GRAFIX CORE 2CM x 3cm (6cm^2)	1	1	Q4132
PS12034	GRAFIX CORE 3cm x 4cm (12cm^2)	1	1	Q4132
PS12055	GRAFIX CORE 5cm x 5cm (25cm^2)	1	1	Q4132

GRAFIX PL◊ PRIME Lyopreserved Placental Membrane

Order No	Size	Each/ unit	Unit/ case	HCPCS
PS13016	16mm disc (2cm^2)	1	1	Q4133
PS13015	1.5cm x 2cm (3cm^2)	1	1	Q4133
PS13023	2cm x 3cm (6cm^2)	1	1	Q4133
PS13033	3cm x 3cm (9cm^2)	1	1	Q4133
PS13034	3cm x 4cm (12cm^2)	1	1	Q4133
PS13055	5cm x 5cm (25cm^2)	1	1	Q4133
PS15055	XC-5cm x 5cm (25cm^2)	1	1	-
PS15077	XC–7cm x 7cm (49cm^2)	1	1	-
PS15075	XC–7.5cm x 15cm (113cm^2)	1	1	-

Ordering information

OASIS® Wound Matrix

Order No	Size	Sheets/box	HCPCS
8213-1000-33	3cm x 3.5cm (10.5cm^2) fenestrated	10	Q4102
8213-1000-37	3cm x 7cm (21cm^2) fenestrated	10	Q4102

OASIS® Burn Matrix

Order No	Size	Sheets/box	HCPCS
8213-3000-16	3cm x 3.5cm (10.5cm^2) fenestrated	5	Q4103
8213-3000-18	3cm x 7cm (21cm^2) fenestrated	5	Q4103
8213-3000-13	5cm x 7cm (35cm^2) meshed	5	Q4103
8213-3000-09	7cm x 10cm (70cm^2) meshed	5	Q4103
8213-3000-11	7cm x 20cm (140cm^2) meshed	5	Q4103

OASIS® XL Matrix

Order No	Size	Sheets/box	HCPCS
8213-3000-20	20cm x 30cm (600cm^2), perforated	1	-

OASIS® ULTRA Tri-Layer Matrix

Order No	Size	Sheets/box	HCPCS
8213-0000-16	3cm x 3.5cm (10.5cm^2) fenestrated	5	Q4124
8213-0000-18	3cm x 7cm (21cm^2) fenestrated	5	Q4124
8213-0000-13	5cm x 7cm (35cm^2) meshed	5	Q4124
8213-0000-09	7cm x 10cm (70cm^2) meshed	5	Q4124
8213-0000-11	7cm x 20cm (140cm^2) meshed	5	Q4124

OASIS® MICRO Micronized Wound Matrix

Order No	Size	Bottles/box	HCPCS
C-ECM-PWD-200MG	200mg (covers approx. 35cm^2)	1	-
C-ECM-PWD-500MG	500 mg (covers approx. 85cm^2)	1	-
C-ECM-PWD-1000MG	1000mg (covers approx. 170cm^2)	1	-

Ordering information

PICO◊ 7 sNPWT System

Order No	Size	Kits/case (2x dressing/kit)
66022002	10cm x 20cm	3
66022003	10cm x 30cm	3
66022004	10cm x 40cm	3
66022005	15cm x 15cm	3
66022006	15cm x 20cm	3
66022007	15cm x 30cm	3
66022008	20cm x 20cm	3
66022009	25cm x 25cm	3

Order No	Size	Kits/case (1x dressing/kit)
66022012	10cm x 20cm	3
66022013	10cm x 30cm	3
66022014	10cm x 40cm	3
66022015	15cm x 15cm	3
66022016	15cm x 20cm	3
66022017	15cm x 30cm	3
66022018	20cm x 20cm	3
66022019	25cm x 25cm	3

PICO◊ 14 sNPWT System

Order No	Size	Kits/case (2x dressing/kit)
66022042	10cm x 20cm	3
66022043	10cm x 30cm	3
66022044	10cm x 40cm	3
66022045	15cm x 15cm	3
66022046	15cm x 20cm	3
66022047	15cm x 30cm	3
66022048	20cm x 20cm	3
66022049	25cm x 25cm	3

PICO◊ sNPWT Accessories

Order No	Size	Each/Unit	Unit/case	HCPCS
66801082	RENASYS Adhesive Gel Patch: 7cm x 10cm	5	10	A6223
66801692	Foam Wound Dressing: 10cm x 12.5cm x 1.5cm	1	5	-
66801691	Antimicrobial Gauze Dressing: 15cm x 17cm	5	10	-

STRAVIX◊ Cryopreserved Umbilical Tissue

Order No	Size	Each/unit	Unit/case	HCPCS
PS60006	2cm x 2cm (4cm²)	1	1	-
PS60005	2cm x 4cm (8cm²)	1	1	-
PS60008	3cm x 6cm (18cm²)	1	1	-
PS60036	3cm x 6cm meshed (18cm²*)	1	1	-

SOLOSITE◊ Wound Gel

Order No	Size	Each/unit	Unit/case	HCPCS
449600	3oz Tube	1	12	A6248

VERSAJET◊ II Hydrosurgery System

Order No	Size	Each/unit	Unit/case
66800041	VERSAJET II EXACT 45°/14mm	1	5
66800042	VERSAJET II EXACT 45°/8mm	1	5
66800040	VERSAJET II EXACT 15°/14mm	1	5
66800044	VERSAJET II PLUS 45°/14mm	1	5
66800045	VERSAJET II PLUS 45°/8mm	1	5
66800043	VERSAJET II PLUS 15°/14mm	1	5

Ordering information

RENASYS◊ TOUCH NPWT System

Order No	Size	Each/unit	Unit/case
66802134	RENASYS TOUCH Pump	1	1
66801286	Power supply (Class 2)	1	1
66801564	Power cord (Class 2)	1	1
66801283	TOUCH O-ring	20	1
66801284	Odor filter	20	1
66021812	Service pack	1	10
66020971	Y-connector	1	1
66801278	RENASYS TOUCH IV/Bed pole clamp	1	1
66801273	300mL canister with solidifier	1	5
66801275	300mL canister without solidifier	1	5
66801274	800mL canister with solidifier	1	5
66801271	800mL canister without solidifier	1	5

RENASYS◊ tNPWT Accessories

Order No	Size	Each/unit	Unit/case	HCPCS
66020794	RENASYS-F, Foam Dressing Kit with Soft Port, Small Kit	1	5	A6550
66020795	RENASYS-F, Foam Dressing Kit with Soft Port, Medium Kit	1	5	A6550
66020796	RENASYS-F, Foam Dressing Kit with Soft Port, Large Kit	1	5	A6550
66020797	RENASYS F, Foam Dressing Kit with Soft Port, X Large Kit	1	5	-
66027659	RENASYS WF, White Foam Small 7.5cm x 10cm x 1cm	10	6	-
66027660	RENASYS WF, White Foam Large 10cm x 15cm x 1cm	1	10	-
66021980	RENASYS-AB, Abdominal Dressing Kit with Soft Port	1	5	-
66801692	Foam Wound Dressing	1	5	-
66020933	RENASYS-G, Gauze Dressing Kit with Soft Port, Small Kit	1	5	A6550
66020934	RENASYS-G, Gauze Dressing Kit with Soft Port, Medium Kit	1	5	A6550
66020935	RENASYS-G, Gauze Dressing Kit with Soft Port, Large Kit	1	5	A6550
66801082	RENASYS Adhesive Gel Patch	10	5	-
66020799	RENASYS Soft Port	1	5	-
66800394	RENASYS Transparent Film (20cm x30cm)	10	10	-
66020853	RENASYS Transparent Film - X LARGE (38cm x 60 cm)	5	5	-
66800391	"NPWT Antimicrobial Large Gauze Roll"	1	10	-
66801691	Antimicrobial Gauze	1	10	A6223

References

References: 1. American Burn Association 2024 Burn Injury Summary Report. **2.** Koenig SM, Deng L, Onwubiko C, Beierle EA, Russell RT. Pediatric Burn Injuries: Risk Factors for Increased Mortality. J Surg Res. 2024 Sep;301:584-590. doi: 10.1016/j.jss.2024.07.016. Epub 2024 Jul 31. PMID: 39089134. **3.** Khan S, Ul Islam Z, Dure Najaf Rizvi S. Epidemiology of elderly burn patients in the United States: Mortality patterns and risk factors revealed by CDC WONDER database. Burns. 2025 Feb;51(1):107311. doi: 10.1016/j.burns.2024.107311. Epub 2024 Nov 9. PMID: 39622090. **4.** Marc G. Jeschke, et al. Nat Rev Dis Primers. 2020 Feb 13;6(1):1. **5.** Khan S, Ul Islam Z, Dure Najaf Rizvi S. Epidemiology of elderly burn patients in the United States: Mortality patterns and risk factors revealed by CDC WONDER database. Burns. 2025 Feb;51(1):107311. doi: 10.1016/j.burns.2024.107311. Epub 2024 Nov 9. PMID: 39622090. **6.** Williams FN, Lee JO. Pediatric Burn Infection. Surg Infect (Larchmt). 2021 Feb;22(1):54-57. doi: 10.1089/sur.2020.218. Epub 2020 Aug 13. PMID: 32790497. **7.** Barret JP, Dziewulski P, Ramzy PI, Wolf SE, Desai MH, Herndon DN. Plastic and Reconstructive Surgery. 2000;105(1):62–65. **8.** Gerding RL, Imbembo AL, Fratianne RB. J Trauma. 1988;28(8):1265–1269. **9.** Wasiak J, Cleland H, Campbell F. Cochrane Database Syst Rev. 2008(4). **10.** Kumar RJ, Kimble RM, Boots R, Pegg SP. ANZ J Surg. 2004;74(8):622-626. **11.** Smith+Nephew 2020.Mode of action of collagen in BIOBRANE wound dressings. Internal Report. EO.AWM.PCS229.001.v1. **12.** Caputo WJ, Beggs DJ, DeFede JL, Simm L, Dharma H. A prospective randomised controlled clinical trial comparing hydrosurgery debridement with conventional surgical debridement in lower extremity ulcers. Int Wound J. 2008;5(2):288-294. **13.** Liu J, Ko JH, Secretov E, et al. Comparing the hydrosurgery system to conventional debridement techniques for the treatment of delayed healing wounds: a prospective, randomised clinical trial to investigate clinical efficacy and cost-effectiveness. Int Wound J. 2015;12(4):456-461. **14.** McAleer JP, Kaplan EM, Perisich G, Axman W. A Prospective Randomized Study Evaluating the Time Efficiency of the VERSAJET™ Hydrosurgery System and Traditional Wound Debridement. Poster presented at: ACFAS 2005; New Orleans, LA. **15.** Hyland EJ, D'Cruz R, Menon S, et al. Prospective, randomised controlled trial comparing Versajet hydrosurgery and conventional debridement of partial thickness paediatric burns. Burns. 2015;41(4):700-707. 2. Matsumura H, Nozaki M, Watanabe K, et al. The Estimation of Tissue Loss During Tangential Hydrosurgical Debridement. Annals Plast Surg. 2012;69(5):521-525. **16.** Rennekampff HA, Schaller HE, Wisser D, Tanenhaus M. Debridement of Burn Wounds with a Water Jet Surgical Tool. Burns. 2006;32(1):64 - 69. **17.** Granick MS, Posnett J, Jacoby M, Noruthun S, Ganchi PA, Datiashvili RO. Efficacy and cost-effectiveness of a high-powered parallel waterjet for wound debridement. Wound Repair Regen. **18.** Granick M, Boykin J, Gamelli R, Schultz G, Tenenhaus M. Toward a common language: surgical wound bed preparation and debridement. Wound Repair Regen. 2006;14:S1-S10. **19.** Vanwijck R, Kaba L, Boland S, Gonzales y Azero M, Delange A, Tourbach S. Immediate skin grafting of sub-acute and chronic wounds debrided by hydrosurgery. J Plast Reconstr Aesthet Surg. **20.** Mosti G, et al. The debridement of chronic leg ulcers by means of a new, fluidjet-based device. Wounds. 2006;18:227-237. **21.** Sivrioğlu N, Irkören S. Versajet hydrosurgery system in the debridement of skin necrosis after Ca gluconate extravasation: report of 9 infantile cases. Acta Orthop Traumatol Turc. 2014;48(1):6-9. **22.** Siemers F, Mauss KL, Liodaki E, Ottomann C, Bergmann PA, Mailänder P. Accidental inclusions following blast injury in esthetical zones: ablation by a hydrosurgery system. Eplasty. 2012;12. **23.** Chammas MF, Gurunluoglu R, Carlsen SN, Molina W, Moore EE, Kim F. Surgical debridement of mineral pitch and nonviable penile tissue using water-jet power: a preliminary report. BJUI. 2008;103(7):974-976. **24.** Allan N, Olson M, Nagel D, Martin R. The impact of hydrosurgical debridement on wounds containing bacterial biofilms. Poster presented at: 20th Meeting of the European Tissue Repair Society 2010; Belgium. **25.** Cubison TCS, Pape SA, Jeffery SLA. Dermal preservation using the Versajet hydrosurgery system for debridement of paediatric burns. Burns. 2006;32:714-720. **26.** Rees-Lee JE, Burge TS, Estela CM. The indications for Versajet® hydrosurgical debridement in burns. Eur J Plast Surg. 2008;31:165-170. **27.** Klein MB, Hunter S, Heimbach DM, et al. The Versajet™ Water Dissector: A New Tool for Tangential Excision. J Burn Care & Rehab 2005;26(6):483-487. **28.** Hassinger SM, Harding G, Wongworawat MD. High-Pressure Pulsatile Lavage Propagates Bacteria into Soft Tissue. Clini Orthop Relat Res. 2005;439:27 - 31. **29.** Herman, I. Stimulation of human keratinocyte migration and proliferation in vitro: insights into the cellular responses to injury and wound healing. Wounds. 1996; 8:33-40. **30.** Riley et al. Collagenase promotes the cellular responses to injury and wound healing in vivo. J Burns Wounds. 2005; 4:112-124. **31.** Shi et al. Degradation of human collagen isoforms by Clostridium collagenase and the effects of degradation products on cell migration. Int Wound J. 2010; 7: 87-95. **32.** Sheets AR, Demidova-Rice TN, Shi L, Ronfard V, Grover KV, Herman IM (2016) Identification and Characterization of Novel Matrix-Derived Bioactive Peptides: A Role for Collagenase from Santyl® Ointment in Post-Debridement Wound Healing? PLoS ONE 11(7): e0159598. **33.** Frederick RE, Bearden R, Jovanovic A, Jacobson N, Sood R, Dhall S. Int J Mol Sci. 2021;22(16):8643. Published 2021 Aug 11. doi:10.3390/ijms22168643. **34.** Khan S, Ul Islam Z, Dure Najaf Rizvi S. Epidemiology of elderly burn patients in the United States: Mortality patterns and risk factors revealed by CDC WONDER database. Burns. 2025 Feb;51(1):107311. doi: 10.1016/j.burns.2024.107311. Epub 2024 Nov 9. PMID: 39622090. **35.** Williams FN, Lee JO. Pediatric Burn Infection. Surg Infect (Larchmt). 2021 Feb;22(1):54-57. doi: 10.1089/sur.2020.218. Epub 2020 Aug 13. PMID: 32790497. **36.** Wright JB, Lam K, Burrell RE. Wound management in an era of increasing bacterial antibiotic resistance: A role for topical silver treatment. Am J Infect Control. 1998;26(6):572–577. **37.** Smith+Nephew 2008. Antimicrobial activity of ACTICOAT Flex 3 against a broad spectrum of wound pathogens. Internal Report. DOF 0810016. **38.** Smith+Nephew 2008. Antimicrobial activity of ACTICOAT Flex 7 against a broad spectrum of wound pathogens. Internal Report. DOF 0810012. **39.** Smith+Nephew 1993. Broad Spectrum Efficacy. Internal Report. Report 93/001. **40.** Smith+Nephew 2008. Antimicrobial activity of ACTICOAT Flex 3 dressings in a 3 day repeat challenge test. Internal Report. DOF 0810017. **41.** Smith+Nephew 2008. Antimicrobial activity of ACTICOAT Flex 7 dressings in a 7 day repeat challenge test. Internal Report. DOF 0810013. **42.** Wright JB, Lam K, Hansen D, Burrell RE. Efficacy of topical silver against fungal burn wound pathogens. Am J Infect Control. 1999;27(4):344–350. **43.** Smith+Nephew 2008. ACTICOAT Flex 3 has antimicrobial activity in 30 minutes. Internal Report. DOF 0810018. **44.** Smith+Nephew 2008. ACTICOAT Flex 7 has antimicrobial activity in 30 minutes. Internal Report. DOF 0810014. **45.** Yin HQ, Langford R, Burrell RE. Comparative evaluation of the antimicrobial activity of ACTICOAT Antimicrobial Barrier Dressing. J Burn Care Rehabil. 1999;20(3):195–200. **46.** Wright JB, Hansen D, Burrell RE. The comparative efficacy of two antimicrobial barrier dressings: In vitro examination of two controlled release of silver dressings. Wounds. 1998;10(6):179–188. **47.** Westaim Biomedical 2001. The antimicrobial activity of Westaim's ACTICOAT Silver coated dressing against clinically relevant organisms over an extended period of time. Fort Saskatchewan, Alberta, Canada. Report - 971030. **48.** Smith+Nephew 2011. A prospective, open, multicentre evaluation of the use of ACTICOAT Flex dressing in the treatment of partial thickness and deep partial thickness burns. Internal Report. SR/CE/036/ACB. **49.** Smith+Nephew 2011. An evaluation of the use of ACTICOAT Flex dressings. Internal Report. SR/CIME/017. **50.** Gago et al (2008) A comparison of Three Silver - containing Dressings in the Treatment of Infected, Chronic Wounds 20(10): 273-278. **51.** Woodmansey EJ, Roberts CD. Appropriate use of dressings containing nanocrystalline silver to support antimicrobial stewardship in wounds. Int Wound J. 2018;15(6):1025 - 1032. **52.** Newton H. Reducing MRSA bacteraemias associated with wounds. Wounds. 2010;6(1):56 - 65. **53.** Strand O, San Miguel L, Rowan S, Sahlqvist A. Retrospective comparison of two years in a paediatric burns unit, with and without ACTICOAT as a standard dressing. Ann Burns Fire Disasters. 2010;23(4):182 - 185. **54.** Fong J, Wood F, Fowler B. A silver coated dressing reduces the incidence of early burn wound cellulitis and associated costs of inpatient treatment: Comparative patient care audits. Burns. 2005;31(5):562 - 567. **55.** Cuttle L, Naidu S, Mill J, Hoskins W, Das K, Kimble RM. A retrospective cohort study of Acticoat versus Silvazine in a paediatric population. Burns. 2007;33(6):701 - 707. **56.** Peters DA, Verchere C. Healing at home: Comparing cohorts of children with medium-sized burns treated as outpatients with in-hospital applied ACTICOAT to those children treated as inpatients with silver

References

sulfadiazine. J Burn Care & Research. 2006;27(2):198 - 201. **57.** Tredget EE, Shankowsky HA, Groenveld A, Burrell RE. A matched-pair, randomised study evaluating the efficacy and safety of ACTICOAT silver-coated dressing for the treatment of burn wounds. J Burn Care Rehabil. 1998;19(6):531 - 537. **58.** Strohal R, Schelling M, Takacs M, Jurecka W, Gruber U, Offner F. Nanocrystalline silver dressings as an efficient anti-MRSA barrier: a new solution to an increasing problem. J Hosp Infect. 2005;60(3):226 - 230. **59.** Chaloner D, Stevens J. A comparative study of two silver containing dressings, ACTICOAT 7 and Avance, in the treatment of chronic venous ulcers. Poster presented at: WUWHS2004; Paris. **60.** Gravante G, Caruso, R., Sorge, R., Nicoli, F., Gentile, P. and Cervelli, V. Nanocrystalline silver: a systematic review of randomized trials conducted on burned patients and an evidence-based assessment of potential advantages over older silver formulations. Annals of plastic surgery. 2009;63:201-205. **61.** Westaim Report Ref. #001213 Long Term Comparative Evaluation of Silverlon and ACTICOAT 7 Dressings against MRSA. **62.** Westaim Report Ref #010322 Seven day efficacy of ACTICOAT 7 Dressings against multiple. **63.** Glik J, Labus W, Kitala D, et al. A 2000 patient retrospective assessment of a new strategy for burn wound management in view of infection prevention and treatment. Int Wound J. 2018;15(3):344 - 349. **64.** Smith+Nephew 2011. A prospective, open, multicentre evaluation of the use of ACTICOAT Flex dressing in the treatment of partial thickness and deep partial thickness burns. Internal Report. SR/CE/036/ACB. **65.** Holder IA, Durkee P, Supp AP, Boyce ST. Assessment of a silver-coated barrier dressing for potential use with skin grafts on excised burns. Burns. 2003;29(5):445 - 448. **66.** Edwards-Jones V. Antimicrobial and barrier effects of silver against methicillin-resistant Staphylococcus aureus. Wound Care. 2006;15(7):285 - 290. **67.** Leahy-Gilmartin A, Edwards-Jones V. Challenging silver: a comparison of in vitro testing methods. Wounds International. 2018;9(2):35 - 42. **68.** Smith+Nephew 2019. Chemical compatibility of ACTICOAT Flex 3 with Negative Pressure Wound Therapy. Internal Statement. PSS383. **69.** Smith+Nephew 2018. Summary wound model report for PICO 7Y - RENASYS Gauze, Foam, ACTICOAT Flex 3, ACTICOAT Flex 7 and RENASYS Adhesive Gel Patches. Internal Report. DS/18/220/R v2. **70.** Smith+Nephew 2011. Wound model investigation of the compatibility of PICO with a range of wound fillers and a wound contact layer. Internal Report. DS/11/021/R1. **71.** Smith+Nephew 2011. The compatibility of ACTICOAT Flex 3 and PICO dressings under NPWT. Internal Report. DOF 1102008. **72.** Leaper DJ, Schultz G, Carville K, et al. Extending the TIME concept: what have we learned in the past 10 years? Int Wound J. 2012; 9 (Suppl 2): 1-19. **73.** Lang EM, Eiberg CA, Brandis M, Stark GB. Ann Plast Surg. 2005;55(5):485–489. **74.** Lal S, Barrow RE, Wolf SE, et al. Shock (Augusta, Ga). 2000;14(3):314–318; 318–319. **75.** Gerding RL, Emerman CL, Effron D, et al. Ann Emerg Med. 1990;19(2):121–124. **76.** Selvarajah D, Bollu BK, Harvey J, et al. Int J Burn Trauma. 2019;9(4):82–87. **77.** Cassidy C, St Peter SD, Lacey S, et al. Burns. **78.** Lesher AP, Curry RH, Evans J, et al. Effectiveness of Biobrane for treatment of partial-thickness burns in children. J Pediatr Surg. 2011;46(9):1759-1763. **79.** Muganza A, Cullingworth L. A Prospective Single-Centre Randomised Controlled Study to Compare the Time to Healing of Partial Thickness Burn Wounds Treated with Versajet, Biobrane and Acticoat Therapy. Glob J Med Res. 2014;14(6):5-12. **80.** Glik J, Kawecki M, Kitala D, et al. A new option for definitive burn wound closure - pair matching type of retrospective case-control study of hand burns in the hospitalised patients group in the Dr Stanislaw Sakiel Centre for Burn Treatment between 2009 and 2015. Int Wound J. 2017;14:849-855. **81.** Salgado RM, Bravo L, García M, Melchor JM, Krötzsch E. Histomorphometric analysis of early epithelialization and dermal changes in mid partial-thickness burn wounds in humans treated with porcine small intestinal submucosa and silver-containing hydrofiber. J Burn Care Res. 2014;35(5):e330-e337. **82.** Cuenca-Pardo J, Peralta-Conde D. Quemaduras en cara ratada con escision temprana y cubiertas con matrix acelular (Face burns treated with early excision and covered with an acellular matrix). Cir Plast. 2011;21(1):11-19. **83.** Haraway GD. The extracellular matrix in wound healing. Malvern, PA: HMP Communications; 2006:1-4. **84.** MacNeil S. What role does the extracellular matrix serve in skin grafting and wound healing? Burns. 1994;20 Suppl 1:S67-S70. **85.** Romanelli M, Gilligan AM, Waycaster CR, Dini V. Difficult-to-heal wounds of mixed arterial/venous and venous etiology: a cost-effectiveness analysis of extracellular matrix. Clinicoecon Outcomes Res. 2016 May 4;8:153-61. doi: 10.2147/CEOR.S104067. PMID: 27217787; PMCID: PMC4862353. **86.** Fong J, Wood F, Fowler B. A silver coated dressing reduces the incidence of early burn wound cellulitis and associated costs of inpatient treatment: comparative patient care audits. Burns. 2005 Aug;31(5):562-7.

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult each product's Instructions for Use (IFU) prior to use.

Important Safety Information Indications: Collagenase SANTYL Ointment ("SANTYL") is a prescription-only medication indicated for debriding chronic dermal ulcers and severely burned areas. **Contraindications:** SANTYL is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase. **Warning and Precautions:** The optimal pH range of collagenase is 6 to 8. Higher or lower pH conditions will decrease the enzyme's activity and appropriate precautions should be taken. The enzymatic activity is also adversely affected by certain detergents, and heavy metal ions such as mercury and silver which are used in some antiseptics. As such, the wound should be properly cleansed prior to application of SANTYL. Debilitated patients should be closely monitored for systemic bacterial infections because of the theoretical possibility that debriding enzymes may increase the risk of bacteremia. A slight transient erythema has been noted occasionally in the surrounding tissue, particularly when SANTYL was not confined to the wound. SANTYL is not indicated for wound closure. Discontinue use of SANTYL after granulation tissue is well-established. **Adverse Reactions:** No allergic sensitivity or toxic reactions have been noted in clinical use when used as directed. The risk information provided herein is not comprehensive. For complete prescribing information, please refer to the accompanying PI or visit: https://santyl.com/sites/default/files/2019-12/ SANTYL-PI.pdf. You are encouraged to report negative side effects of prescription drugs to FDA. Visit MedWatch or call 1-800-FDA-1088.

OASIS® Wound Matrix is derived from a porcine source and should not be used in patients with known sensitivity to porcine materials. This device is not indicated for use in third degree burns. OASIS Matrix Products manufactured by: Cook Biotech, Inc. 1425 Innovation Place West, Lafayette, IN 47906, USA OASIS Matrix Products distributed by: Smith & Nephew, Inc. Fort Worth, TX 76109, USA | OASIS trademark is a trademark of Cook Biotech Incorporated

Advanced Wound Management
Smith & Nephew, Inc.
Fort Worth, TX 76109 USA

T 800-876-1261
F 727-392-6914
www.smith-nephew.com